-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on BeOne Medicines, Raises Price Target to $476

Benzinga·11/13/2026 17:58:24
Listen to the news
Morgan Stanley analyst Sean Laaman maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises the price target from $465 to $476.